S133 Improvements in FEV1 and St George’s respiratory questionnaire (SGRQ) at 4 and 16 weeks on benralizumab are strongly associated with clinical remission at 1 year

Résumé fourni par la source

Introduction Remission is now an aspiration for asthma patients on biologics, although there is no agreed definition. Predicting the likelihood of remission at an early stage on treatment would improve precision therapy. Aims To identify the characteristics at 4 and 16 weeks on treatment associated with remission at 1 year in a real-world asthma cohort on benralizumab. Methods BenRex is a multicentre study of exacerbations on benralizumab for severe eosinophilic asthma. We defined remission at 1 year as meeting all of: no OCS for asthma (for maintenance/exacerbation); ACQ <1.5 and FEV1 ≥ 80% predicted and/or ≥ 10% higher than baseline FEV1% predicted. Forest plots of associations between early changes at 4 and 16 weeks and remission at 1 year were derived from logistic regression models. Results 36 of 136 subjects (26.5%) met remission criteria. Subjects achieving remission were older (p=0.04). Male and female participants achieved remission at similar rates (p=0.84). Figure 1 shows predictors of remission using changes from baseline at 4 and 16 weeks. FEV1 and SGRQ improvement are strongly associated with subsequent remission. Conclusion An improvement in FEV1 of ≥100 ml and SGRQ change of double the MCID at 4 and 16 weeks on benralizumab are strongly associated with clinical remission at one year.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.